Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines

  • Lee, Hyunju (Department of Pediatrics, Seoul National University Bundang Hospital) ;
  • Choi, Eun Hwa (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Lee, Hoan Jong (Department of Pediatrics, Seoul National University Children's Hospital)
  • 투고 : 2013.09.07
  • 심사 : 2014.01.24
  • 발행 : 2014.02.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The 7-valent pneumococcal protein conjugate vaccine (PCV7) has been shown to be highly efficacious against invasive pneumococcal diseases and effective against pneumonia and in reducing otitis media. The introduction of PCV7 has resulted in major changes in the epidemiology of pneumococcal diseases. However, pneumococcal vaccines induce serotype-specific immunity, and a relative increase in non-vaccine serotypes has been reported following the widespread use of PCV7, leading to a need for extended serotype coverage for protection. PCV10 and PCV13 have been licensed on the basis of noninferiority of immunogenicity compared to a licensed conjugate vaccine. In this article, we aimed to review important data regarding the efficacy and effectiveness of the extended-coverage PCVs published or reported thus far and to discuss future implications for pneumococcal vaccines in Korea. After the introduction of PCV10 and PCV13, within a short period of time, evidence of protection conferred by these vaccines against invasive and mucosal infections caused by most of the serotypes included in the vaccines is accumulating. The choice of vaccine should be based on the changes in the dynamics of pneumococcal serotype distribution and diseases in the region where the vaccines are to be used. Continuous surveillance is essential for the appropriate use of pneumococcal vaccines and evaluation of the impact of PCVs on pneumococcal diseases.

키워드

참고문헌

  1. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995;33:2759-62.
  2. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-9):1-35.
  3. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010;7( 10):e1000348. https://doi.org/10.1371/journal.pmed.1000348
  4. Cho EY, Kang HM, Lee J, Kang JH, Choi EH, Lee HJ. Changes in serotype distribution and antibiotic resistance of nasopharyngeal isolates of Streptococcus pneumoniae from children in Korea, after optional use of the 7-valent conjugate vaccine. J Korean Med Sci 2012;27:716-22. https://doi.org/10.3346/jkms.2012.27.7.716
  5. Kim KH, Hong JY, Lee H, Kwak GY, Nam CH, Lee SY, et al. Nasopharyngeal pneumococcal carriage of children attending day care centers in Korea: comparison between children immunized with 7-valent pneumococcal conjugate vaccine and non-immunized. J Korean Med Sci 2011;26:184-90. https://doi.org/10.3346/jkms.2011.26.2.184
  6. Ahn JG, Choi SY, Kim DS, Kim KH. Enhanced detection and serotyping of Streptococcus pneumoniae using multiplex polymerase chain reaction. Korean J Pediatr 2012;55:424-9. https://doi.org/10.3345/kjp.2012.55.11.424
  7. Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee J, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008;14:275-81. https://doi.org/10.3201/eid1402.070807
  8. WHO Publication. Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine 2012;30:4717-8. https://doi.org/10.1016/j.vaccine.2012.04.093
  9. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008;57:144-8.
  10. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. MMWR Morb Mortal Wkly Rep 2010;59:253-7.
  11. Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010;59:258-61.
  12. Vaccines, Blood & Biologics. Prevnar 13 (pneumococcal 13-valent conjugate vaccine) [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2014 [cited 2013 Aug 5]. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/Approved Products/ucm201667.htm.
  13. U.S. Food and Drug Administration. Prevnar 13: clinical review of new product license application. Silver Spring (MD): U.S. Food and Drug Administration, 2010.
  14. Synflorix, pneumococcal polysaccharide conjugate vaccine (adsorbed): summary of product characteristics [Internet]. London: European Medicines Agency; c1995-2014 [cited 2013 Aug 5]. Available from: http://www.ema.europa.eu/docs/en_GB/docu ment_library/EPAR_-_Product_Information/human/000973/WC5 00054346.pdf.
  15. Expert Committee on Biological Standardization, Geneva, 19 to 23 October 2009. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. Replacement of: TRS 927, Annex 2 [Internet]. Geneva: World Health Organization; c2009 [cited 2013 Aug 5]. Available from: http://www.who.int/biologicals/areas/vaccines/pneumo/Pneumo_final_23APRIL_2010.pdf?ua=1.
  16. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 2012;11:841-55. https://doi.org/10.1586/erv.12.53
  17. O'Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, Reid R, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 2007;196:1211-20. https://doi.org/10.1086/521833
  18. Parra EL, De La Hoz F, Díaz PL, Sanabria O, Realpe ME, Moreno J. Changes in Streptococcus pneumoniae serotype distribution in invasive disease and nasopharyngeal carriage after the heptavalent pneumococcal conjugate vaccine introduction in Bogota, Colombia. Vaccine 2013;31:4033-8. https://doi.org/10.1016/j.vaccine.2013.04.074
  19. Neves FP, Pinto TC, Correa MA, dos Anjos Barreto R, de Souza Gouveia Moreira L, Rodrigues HG, et al. Nasopharyngeal carriage, serotype distribution and antimicrobial resistance of Streptococcus pneumoniae among children from Brazil before the introduction of the 10-valent conjugate vaccine. BMC Infect Dis 2013;13:318. https://doi.org/10.1186/1471-2334-13-318
  20. Davis S, Deloria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: Review of evidence on indirect effects. Vaccine 2013 Dec 17 [Epub]. http://dx.doi.org/ 10.1016/j.vaccine.2013.05.005.
  21. Flasche S, Van Hoek AJ, Sheasby E, Waight P, Andrews N, Sheppard C, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 2011;8:e1001017. https://doi.org/10.1371/journal.pmed.1001017
  22. Ghaffar F, Barton T, Lozano J, Muniz LS, Hicks P, Gan V, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004;39:930-8. https://doi.org/10.1086/423379
  23. Moore MR, Hyde TB, Hennessy TW, Parks DJ, Reasonover AL, Harker-Jones M, et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J Infect Dis 2004;190:2031-8. https://doi.org/10.1086/425422
  24. Sharma D, Baughman W, Holst A, Thomas S, Jackson D, da Gloria Carvalho M, et al. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Pediatr Infect Dis J 2013;32:e45-53. https://doi.org/10.1097/INF.0b013e31827842c9
  25. Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012;31:297-301. https://doi.org/10.1097/INF.0b013e318247ef84
  26. Desai AP SD, Crispell E, Baughman W, Thomas S, Holst A. Pneumococcal nasopharyngeal carriage in children in Atlanta, Georgia in the post-PCV13 era. In: IDWeek 2012 Advancing Science, Improving Care; 2012 Oct 17-21; San Diego (CA), USA.
  27. Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013;57:952-62. https://doi.org/10.1093/cid/cit428
  28. Spijkerman J, Prevaes SM, van Gils EJ, Veenhoven RH, Bruin JP, Bogaert D, et al. Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PLoS One 2012;7:e39730. https://doi.org/10.1371/journal.pone.0039730
  29. Prymula R, Hanovcova I, Splino M, Kriz P, Motlova J, Lebedova V, et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine 2011;29:1959-67. https://doi.org/10.1016/j.vaccine.2010.12.086
  30. van den Bergh MR, Spijkerman J, Swinnen KM, Francois NA, Pascal TG, Borys D, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis 2013;56:e30-9. https://doi.org/10.1093/cid/cis922
  31. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-9. https://doi.org/10.1056/NEJM200102083440602
  32. Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004;23:829-33. https://doi.org/10.1097/01.inf.0000136868.91756.80
  33. Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. Pediatr Infect Dis J 1992;11(8 Suppl):S7-11. https://doi.org/10.1097/00006454-199208001-00002
  34. Fletcher MA, Fritzell B. Pneumococcal conjugate vaccines and otitis media: an appraisal of the clinical trials. Int J Otolaryngol 2012;2012:312935.
  35. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003;22:10-6. https://doi.org/10.1097/00006454-200301000-00006
  36. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95. https://doi.org/10.1097/00006454-200003000-00003
  37. Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003;37:1155-64. https://doi.org/10.1086/378744
  38. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003;362:355-61. https://doi.org/10.1016/S0140-6736(03)14022-6
  39. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367:740-8. https://doi.org/10.1016/S0140-6736(06)68304-9
  40. Sarasoja I, Jokinen J, Lahdenkari M, Kilpi T, Palmu AA. Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements. Pediatr Infect Dis J 2013;32:517-20. https://doi.org/10.1097/INF.0b013e31827c9bcc
  41. De Wals P, Erickson L, Poirier B, Pepin J, Pichichero ME. How to compare the efficacy of conjugate vaccines to prevent acute otitis media? Vaccine 2009;27:2877-83. https://doi.org/10.1016/j.vaccine.2009.02.102
  42. Grijalva CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006;118:865-73. https://doi.org/10.1542/peds.2006-0492
  43. Jardine A, Menzies RI, Deeks SL, Patel MS, McIntyre PB. The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia. Pediatr Infect Dis J 2009; 28:761-5. https://doi.org/10.1097/INF.0b013e31819e9bc5
  44. Taylor S, Marchisio P, Vergison A, Harriague J, Hausdorff WP, Haggard M. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis 2012;54:1765-73. https://doi.org/10.1093/cid/cis292
  45. Alonso M, Marimon JM, Ercibengoa M, Perez-Yarza EG, Perez-Trallero E. Dynamics of Streptococcus pneumoniae serotypes causing acute otitis media isolated from children with spontaneous middle-ear drainage over a 12-year period (1999-2010) in a region of northern Spain. PLoS One 2013;8:e54333. https://doi.org/10.1371/journal.pone.0054333
  46. Saez-Llorens X CM, Rowley S, Wong D, Calvo A, Rodriguez M, Troitino M, et al. Efficacy of 10-valent pneumococcal non-typable Haemophilus influenzaeprotein D conjugate vaccine (PHID-CV) against acute otitis media in children in Panama. In: The 9th International Symposium on Antimicrobial Agents and Resistance; 2013 Mar 13-15; Kuala Lumpur, Malaysia.
  47. Dagan R G-LN, Leibovitz E, Greenberg D. Incidence dynamics of culture-proven otitis media 4 years before and 3 years after introduction of pneumococcal conjugate vaccines (PCVs) in Southern Israel. In: IDWeek 2012 Advancing Science, Improving Care; 2012 Oct 17-21; San Diego (CA), USA.
  48. Dagan R, Greenberg D, Leibovitz E, Raiz S, Ben-Shimol S, Givon-Lavi N. Trends in serotype-specific pneumococcal carriage in children visiting pediatric emergency room (PER) post PCV7 and PCV13 introduction correlate with trends in serotype-specific otitis media (OM) incidence. In: IDWeek 2013 Advancing Science, Improving Care; 2013 Oct 2-6; San Fransisco (CA), USA.
  49. Cherian T, Mulholland EK, Carlin JB, Ostensen H, Amin R, de Campo M, et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ 2005;83:353-9.
  50. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21:810-5. https://doi.org/10.1097/00006454-200209000-00005
  51. Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006;25:779-81. https://doi.org/10.1097/01.inf.0000232706.35674.2f
  52. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005;365:1139-46. https://doi.org/10.1016/S0140-6736(05)71876-6
  53. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-8. https://doi.org/10.1056/NEJMoa035060
  54. Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005;40:1511-8. https://doi.org/10.1086/429828
  55. Lucero MG, Nohynek H, Williams G, Tallo V, Simoes EA, Lupisan S, et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J 2009;28:455-62. https://doi.org/10.1097/INF.0b013e31819637af
  56. Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreno RA, Nohynek H, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009;(4):CD004977.
  57. Hortal M, Sehabiague G, Camou T, Iraola I, Estevan M, Pujadas M. Pneumococcal pneumonia in hospitalized Uruguayan children and potential prevention with different vaccine formulations. J Pediatr 2008;152:850-3. https://doi.org/10.1016/j.jpeds.2007.11.008
  58. Varela MS CM, Helios M, Facal J, Pirez MC, Algorta G. Impact of children universal pneumococcal vaccination (PCV7V/PCV13V) on hospitalizations for pneumonia and pneumococcal invasive disease in the British hospital, Uruguay. In: The 8th International Symposium on Pnuemococci and Pneumococcal Diseases; 2012 Mar 11-15; Iguacu Falls, Brazil.
  59. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007;369:1179-86. https://doi.org/10.1016/S0140-6736(07)60564-9
  60. Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J 2010;29:607-12. https://doi.org/10.1097/INF.0b013e3181d7d09c
  61. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013;369:155-63. https://doi.org/10.1056/NEJMoa1209165
  62. Afonso ET, Minamisava R, Bierrenbach AL, Escalante JJ, Alencar AP, Domingues CM, et al. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis 2013; 19:589-97. https://doi.org/10.3201/eid1904.121198
  63. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41. https://doi.org/10.1086/648593
  64. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011;378:1962-73. https://doi.org/10.1016/S0140-6736(10)62225-8
  65. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol Rec 2010;85:434-6.
  66. Williams SR, Mernagh PJ, Lee MH, Tan JT. Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine. Med J Aust 2011;194:116-20.
  67. Lehmann D, Willis J, Moore HC, Giele C, Murphy D, Keil AD, et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 2010;50:1477-86. https://doi.org/10.1086/652440
  68. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009;49:205-12. https://doi.org/10.1086/599827
  69. Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013;32:203-7. https://doi.org/10.1097/INF.0b013e318275614b
  70. Singleton R, Wenger J, Klejka JA, Bulkow LR, Thompson A, Sarkozy D, et al. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatr Infect Dis J 2013;32:257-63.
  71. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011;29:9127-31. https://doi.org/10.1016/j.vaccine.2011.09.112
  72. Health Protection Agency. Current epidemiology of invasive pneumococcal disease (IPD) [Internet]. London: Immunisation Department, Public Health England; [cited 2013 Aug 23]. Available from: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/InPrevenar7/pneumo03Cummulativeweekly5INPrevenar7vacc/.
  73. Moore M, Link-Gelles R, Farley MM, Schaffner W, Thomas A, Reingold A, et al. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, U.S, 2010-11. In: ID Week 2012 Advancing Science, Improving Care; 2012 Oct 17-21; San Diego (CA), USA.
  74. De Wals P LB, Markowski F, Deceuninck G, Defay F, Boulianne N. Invasive pneumococcal disease in birth cohorts vaccinated with PCV7 and/or PHiD-CV in Quebec: an update. In: The 31st Meeting of the European Society for Paediatric Infectious Diseases; 2013 May 28-June 1; Milan, Italy.
  75. Institute of Environmental Science and Research Ltd, New Zealand. Invasive Pneumococcal Disease Reports [Internet]. Wellington (NZ): Population and Environmental Health Institute of Environmental Science & Research Limited Kenepuru Science Centre; [cited 2014 Jan 30]. Available from: http://www.surv.esr.cri.nz/surveillance/IPD.php.
  76. Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013;381:214-22. https://doi.org/10.1016/S0140-6736(12)61854-6
  77. Lee TJ CJ, Kim KH, Kim KJ, Kim DS. Serotype distribution of pneumococcus isolated from the ear discharge in children with otitis media in 2001-2006. Korean J Pediatr Infect Dis 2008;15:44-50.
  78. Lee JH, Cho HK, Kim KH, Kim CH, Kim DS, Kim KN, et al. Etiology of invasive bacterial infections in immunocompetent children in Korea (1996-2005): a retrospective multicenter study. J Korean Med Sci 2011;26:174-83. https://doi.org/10.3346/jkms.2011.26.2.174
  79. Cho EY, Kim YJ, Eun BW, Kim YK, Cho DS, Lee HS, et al. Causative pathogens among childhood bacterial invasive infection in Korea; a multicenter study, 2006-2010. In: The 2012 Annual Meeting of the Korean Society of Pediatric Infectious Diseases; 2012 Nov 10; Seoul, Korea.
  80. Cho EY, Lee H, Choi EH, Kim YJ, Eun BW, Cho YK, et al. Serotype and antibiotic resistance of Streptococcus pneumoniaeisolates from invasive infectionsafter optional use of the 7-valent conjugate vaccinein Korea, 2006-2010. Diagn Microbiol Infect Dis Forthcoming 2014. http://authors.elsevier.com/sd/article/S073288 9314000066.
  81. Choe YJ, Yang JJ, Park SK, Choi EH, Lee HJ. Comparative estimation of coverage between national immunization program vaccines and non-NIP vaccines in Korea. J Korean Med Sci 2013;28:1283-8. https://doi.org/10.3346/jkms.2013.28.9.1283
  82. Cho EY, Choi EH, Lee H, Kang JH, Kim KH, Lee HJ, et al. Multicentric approach for analysis of serotypes of pneumococcus isolated from invasive infections in Korean children. Korea [abstract]. In: The 2013 Annual Meeting of the Korean Society of Pediatric Infectious Diseases; 2013 Nov 9; Seoul, Korea
  83. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11:760-8. https://doi.org/10.1016/S1473-3099(11)70090-1

피인용 문헌

  1. The dichotomy of pathogens and allergens in vaccination approaches vol.5, pp.None, 2014, https://doi.org/10.3389/fmicb.2014.00365
  2. The host immune dynamics of pneumococcal colonization: Implications for novel vaccine development vol.10, pp.12, 2014, https://doi.org/10.4161/21645515.2014.979631
  3. Pneumococcal vaccine vol.57, pp.9, 2014, https://doi.org/10.5124/jkma.2014.57.9.780
  4. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough vol.14, pp.3, 2014, https://doi.org/10.1586/14760584.2015.965160
  5. Next generation protein basedStreptococcus pneumoniaevaccines vol.12, pp.1, 2014, https://doi.org/10.1080/21645515.2015.1052198
  6. Antibiotic Control Policies in South Korea, 2000-2013 vol.48, pp.3, 2014, https://doi.org/10.3947/ic.2016.48.3.151
  7. The prevention of pneumococcal infections vol.5, pp.1, 2014, https://doi.org/10.7774/cevr.2016.5.1.3
  8. Pneumonia and Streptococcus pneumoniae vaccine vol.40, pp.8, 2014, https://doi.org/10.1007/s12272-017-0933-y
  9. Low utility of blood culture in pediatric community-acquired pneumonia: An observational study on 2705 patients admitted to the emergency department vol.96, pp.22, 2014, https://doi.org/10.1097/md.0000000000007028
  10. Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly vol.11, pp.None, 2014, https://doi.org/10.2147/rmhp.s130405
  11. Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collabo vol.13, pp.11, 2014, https://doi.org/10.1371/journal.pone.0206927
  12. Efficacy and Effectiveness of the PCV-10 and PCV-13 Vaccines Against Invasive Pneumococcal Disease vol.145, pp.4, 2014, https://doi.org/10.1542/peds.2019-0377
  13. Prevalence and Antimicrobial Susceptibility of Streptococcus pneumoniae Isolated from Clinical Samples in the Past 8 Years in Korea vol.2021, pp.None, 2014, https://doi.org/10.1155/2021/6615334
  14. Profile of Streptococcus pneumoniae Serotypes of Children with Invasive Disease in Tehran, Iran. An Implication for Vaccine Coverage vol.31, pp.2, 2014, https://doi.org/10.5812/ijp.106086
  15. Emergence of serotype 10A-ST11189 among pediatric invasive pneumococcal diseases, South Korea, 2014–2019 vol.39, pp.40, 2014, https://doi.org/10.1016/j.vaccine.2021.08.072